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Objectives: Ischemia–reperfusion injury remains a devastating complication of lung transplantation. Phospho-
diesterase inhibitors have been shown to precondition tissues against ischemia–reperfusion injury. Little is
known, however, about the utility of phosphodiesterase inhibition in reperfusion injury after lung transplantation.
We evaluated the long-acting phosphodiesterase-5 inhibitor, tadalafil, in an ex vivo lung transplant model.
Methods: New Zealand White rabbits (4 kg), were given oral tadalafil (n¼ 11) 24 hours before lung harvest and
compared with rabbits given oral vehicle alone (n¼ 11). Lungs were recovered with Perfadex solution (Vitrolife,
Kungsbacka, Sweden) and cold stored for 18 hours. After storage, lung blocks were reperfused with donor rabbit
blood in an ex vivo apparatus. Pulmonary artery pressures were recorded with serial arterial and venous blood gas
sampling and animals served as their own controls. Phosphodiesterase-5 and protein kinase G tissue activity as-
says confirmed drug effects. Luminol chemiluminescence assay was used to measure reactive oxygen species and
levels of endothelial and inducible nitric oxide synthase were measured.
Results: Extended cold storage, followed by reperfusion produced a consistent reproducible decrease in oxygen-
ation and increase in pulmonary pressure. Tadalafil-treated animals exhibited greater PaO2 throughout the course
of reperfusion (P ¼ .001) Mean pulmonary artery pressure was lower in tadalafil-treated animals (22 vs 40 mm
Hg; P¼ .04). Phosphodiesterase-5 activity was decreased (143 8 vs 205 32 mP; P<.001) with protein kinase
G activity increased (25  12 vs 12  2.4 fU/mg; P ¼ .01) in the experimental group confirming that oral pre-
treatment resulted in active phosphodiesterase inhibition in the lung tissue. Reactive oxygen species (as measured
by luminol activity) were decreased in tadalafil-treated animals (7.8  1.5 vs 10.2  1.2 relative light units;
P ¼ .003).
Conclusions: Our experimental model demonstrates that oral donor pretreatment with a long-acting phosphodi-
esterase inhibitor is an effective strategy for improving pulmonary performance after reperfusion. Importantly,
phosphodiesterase enzymes and their downstream effectors may play a critical role in reperfusion injury after
lung transplantation.T
XDespite 20 years of successful lung transplantation, primary
graft dysfunction (PGD) remains a significant and devastat-
ing cause of early postoperative respiratory failure.1,2 Occur-
ring in up to 20% of lung transplant recipients, PGD is
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emia, increased pulmonary pressures, and pulmonary
edema.3 Patients in whom PGD develops have increased
rates of rejection and infection, longer intensive care unit
and hospital lengths of stay, and greater short- and long-
term mortality.1,2,4-7
Alterations in pulmonary vascular resistance, microvas-
cular permeability, and gas exchange support the belief
that injury in PGD is primarily caused by ischemia and re-
perfusion (IR).8 Several studies have suggested an important
role for nitric oxide (NO) signaling pathways mediated by
secondary messengers such as cyclic guanosine monophos-
phate (GMP). Models of lung IR injury have demonstrated
that reduced levels of cyclic GMP9 and low levels of cyclic
GMP after lung reperfusion have been associated with the
development of pulmonary hypertension,10 reduced oxy-
genation,11 and increased microvascular permeability.8,10
The importance of NO signaling via cyclic GMP suggests
an opportunity for preconditioning via modulation of this
pathway. The phosphodiesterase (PDE) enzymes represent
a class of 11 distinct isoenzymes responsible for hydrolysis
of cyclic nucleotides.12 Of these, PDE5 is perhaps the best
known because of its high specificity for cyclic GMP andardiovascular Surgery c Volume 137, Number 5 1249
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XAbbreviations and Acronyms
eNOS ¼ endothelial nitric oxide synthase
GEE ¼ generalized estimating equation
GMP ¼ guanosine monophosphate
iNOS ¼ inducible nitric oxide synthase
IR ¼ ischemia and reperfusion
NO ¼ nitric oxide
NOS ¼ nitric oxide synthase
PA ¼ pulmonary artery
PAP ¼ pulmonary artery pressure
PCO2 ¼ partial pressure of carbon dioxide
PDE ¼ phosphodiesterase
PGD ¼ primary graft dysfunction
PKG ¼ protein kinase G
PO2 ¼ partial pressure of oxygen
RM-ANOVA ¼ repeated-measures analysis of
variance
ROS ¼ reactive oxygen species
availability of specific Food and Drug Administration–ap-
proved inhibitors used primarily for the treatment of erectile
dysfunction and pulmonary hypertension. Through augmen-
tation of cyclic GMP levels, PDE inhibition may protect
against the deleterious effects of IR injury after lung trans-
plantation.
Tadalafil (Cialis; Lilly ICOS, Indianapolis, Ind) is a selec-
tive PDE5 inhibitor that was approved for the treatment of
erectile dysfunction in 2003. Tadalafil is distinct from other
commonly used selective PDE5 inhibitors (ie, sildenafil or
vardenafil) in that it possesses a substantially longer
half-life (17.5 hours).13-15 Tadalafil is furthermore readily
bioavailable when administered orally, reaching peak levels
approximately 2 hours after administration. Because of
these pharmacokinetic properties, tadalafil is a potentially
attractive agent for donor preconditioning before lung
transplantation.
Although much research has focused on treatment of IR
at the recipient level, few studies have investigated donor
preconditioning as a means to prevent IR injury after trans-
plantation. Further, to our knowledge, no study has investi-
gated the use of oral tadalafil as a preconditioning agent.
Given the potential therapeutic role for PDE inhibition in
PGD, we hypothesized that pretreatment with a long-acting
oral selective PDE5 inhibitor will reduce reperfusion injury
and graft dysfunction in an ex vivo experimental model of
lung transplantation.
METHODS
Model
We conducted these experiments with an ex vivo lung reperfusion model
whereby rabbit lungs are externally ventilated and perfused with donor rab-
bit blood. The experiment used male New Zealand White rabbits (Myrtle’s1250 The Journal of Thoracic and Cardiovascular SuRabbitry Inc, Thompson Station, Tenn) weighing 3 to 4 kg. All studies were
approved by the Animal Care and Use Committee at the Johns Hopkins
University.
Experimental Protocol
Protocol in brief. A total of 26 rabbits were arbitrarily divided into 2
experimental groups and underwent en bloc heart–lung harvest followed by
18 hours of cold storage. These heart–lung blocks were reperfused (18 hours
after harvest) with donor rabbit blood for 180 minutes while physiologic
data were recorded.
Experimental Groups
Thirteen animals (experimental group) received 1 mg of oral tadalafil
(Toronto Research Chemicals, Inc, North York, Ontario, Canada) dissolved
in 0.5 mL of dimethyl sulfoxide (JHU Core Store; Sigma Chemical Co, St
Louis, Mo) 6 hours before lung harvest (24 hours before reperfusion). The
second set of 13 rabbits (control group) received 1 mL of oral dimethyl sulf-
oxide only administered in an identical time frame. Four animals were
excluded owing to technical complications relating to surgery. In all 4 cases,
a pulmonary artery (PA) injury occurred during harvest (see procedure
below) and when it became clear that PA perfusion was compromised,
the experiment was aborted with no additional data collected. The final
study population thus comprised 22 subjects (11 experimental and 11
controls).
Heart–Lung Block Harvest
Experimental rabbits were anesthetized with intramuscular injection of
ketamine (35 mg/kg) and xylazine (6.5 mg/kg) with intravenous aceproma-
zine (5 mg/kg) given as needed for additional sedation. A tracheotomy was
performed for endotracheal intubation and mechanical ventilation (forced
expiratory volume in 1 second 100%) was initiated (Harvard ventilator
apparatus, model 665; Harvard Apparatus Co, Holliston, Mass). Through
a midline incision and medium sternotomy, the chest was entered and the
superior and inferior venae cavae, aorta, and PA were isolated. Intravenous
heparin (1000 U/kg) was given, and 30 mg of prostaglandin E1 was admin-
istered directly into the PA. The PA was cannulated via a right ventriculot-
omy. An incision was made within the left ventricle for venting, and cold
(4C) Perfadex solution (Vitrolife, Kungsbacka, Sweden) was run by grav-
ity drainage into the lungs through the PA cannula. The superior and inferior
venae cavae and aorta were ligated and a left atrial cannula was placed
through the left ventricle. After placement of cannulas, cold ice slush was
placed surrounding the heart–lung block, and this block was excised from
within the mediastinum. The lungs were inflated, and the block was placed
within a bag of Perfadex solution and cold stored (4C) for 18 hours.
Perfusion Pump System
After cold storage, the heart–lung block was suspended by the trachea
and ventilated at 10 mL/kg, 30 breaths/min, at 100% forced expiratory vol-
ume in 1 second. Two donor rabbits were heparinized (1000 U/kg) and ex-
sanguinated to obtain approximately 300 mL of whole blood. All animals
were perfused for 180 minutes with this donor blood using a Sarns 5000
roller head pump (Sarns, Inc, Ann Arbor, Mich). Arterial blood removed
from the left atrial cannula was collected in a reservoir and deoxygenated
to achieve a PO2 and PCO2 of 60 mm Hg (simulating venous blood). Venous
blood was then pumped into the PA cannula for reperfusion.
Hemodynamic Measurements
Physiologic measurements were recorded initially and then every 15
minutes for the full 180 minutes of perfusion. Pressure transducers recorded
pressures for fluid-filled lines including PA and left atrial pressures. Arterial
and venous blood sampes were collected every 15 minutes for blood gas
sampling (arterial blood gas analyzer, model 348, Chiron Diagnostics, Nor-
wood, Mass).rgery c May 2009
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Lung samples were taken at four time points during the experiment:
immediately after harvest (before cold storage), immediately before perfu-
sion (after cold storage), and then at 1 and 3 hours after perfusion. Lung
samples were removed sharply with the aid of hemoclips for hemostasis
(large ligating clips; Weck, Research Triangle Park, NC). Samples were
snap frozen in liquid nitrogen and stored at80C for later biochemical
analysis.
Wet/Dry Ratios
Wet/dry ratios were obtained to determine levels of pulmonary edema.
Right lower lobe samples were removed and weighed after the full 180 min-
utes of perfusion. These samples were allowed to dry completely and sub-
sequently were reweighed for ratio determination.
PDE5A and Protein Kinase G (PKG) Activity
Total low-kinetic rate constant (Km) cyclic GMP PDE activity was
assayed with a fluorescence polarization assay (Molecular Devices,
Sunnyvale, Calif) and results were read on a Spectramax M5 plate reader
(Molecular Devices). PKG-1 activity was assayed from lung tissue lysates
with a colorimetric analysis (CycLex Co, Ltd, Nagano, Japan).16
Cyclic GMP Levels
Cyclic GMP concentration in whole lung lysates was determined with
a commercially available colormetric assay performed according to the
manufacturer’s specifications (Amersham Pharmaceuticals, Buckingham-
shire, United Kingdom).17
Reactive Oxygen Species (ROS)
ROS were examined by use of a luminol enhanced chemiluminescence
assay (EMD Biosciences, San Diego, Calif). Fresh frozen lung tissue was
homogenized in iced phosphate-buffered saline buffer, centrifuged, and re-
suspended in assay buffer to a concentration of 100 mL luminol. Results
were read on a Spectramax M5 plate reader.18
Nitric Oxide Synthase (NOS) Activity
NOS activity was obtained from lung tissue lysates via a [3H]-L-arginine
to [3H]-L citrulline conversion (Sigma-Aldrich, St Louis, Mo).17,19
Statistical Analysis
For physiologic data (ie, partial pressure of oxygen, PO2; partial pressure
of carbon dioxide, PCO2; and mean pulmonary artery pressure, PAP), two
independent statistical tests were conducted to assess differences between
treatment groups accounting for the longitudinal nature of the repeated mea-
sures over time. First, repeated-measures analysis of variance (RM-AN-
OVA) was performed to examine the effects of tadalafil measured across
13 distinct time points. Post hoc comparisons at specific time points were
conducted with the Tukey honest significant difference test. Multilevel ran-
dom effects modeling was also performed to account for interactions both
between and within each animal. The model used (generalized estimating
equation, GEE) estimated the variance in the physiologic parameter of inter-
est between animals and across time. Values for both the RM-ANOVA and
GEE are presented when discussing treatment effects on physiologic param-
eters. Results of biochemical activity assays (performed on a subset of an-
imals (n ¼ 15) were compared for each point of measurement using the
Student t test (due to a priori expectations of differences for each sample).
When prestorage and postperfusion values within groups were compared,
the paired comparisons Student t test was used. Data are presented as means
 standard deviation. All statistical analyses were conducted with the aid of
STATA software (version 9.2 special edition, Stata Corporation LP, College
Station, Tex).The Journal of Thoracic and CaRESULTS
Physiologic Data
Extended cold storage followed by reperfusion produced
consistent deleterious effects in lung performance among
control animals. Specifically, arterial partial pressures of ox-
ygen (PaO2) and carbon dioxide (PCO2) obtained from the left
atrial cannulas consistently decreased over the 180 minutes
of reperfusion (Table 1 and Figure 1). Control animals dem-
onstrated increases in mean PAP during the study period as
well (Table 1 and Figure 2).
Animals pretreated with oral tadalafil had higher PaO2
levels across the entire time of reperfusion when compared
with control animals (P< .001 by RM-ANOVA) (Table
1). In addition, post hoc testing revealed pretreatment to
be associated with higher PaO2 levels at 90, 120, and 150
minutes after reperfusion by the Tukey honest significant
difference test (Table 1). Random effects modeling sug-
gested that tadalafil pretreatment was associated with an av-
erage PO2 increase of 117 mm Hg (P ¼ .02). By contrast,
PCO2 levels were not different between groups (Figure 1,
B). Mean PAPs were lower in animals treated with tadalafil
(P¼ .006 by RM-ANOVA) and decreased by an average 17
mm Hg (P ¼ .008 by GEE). Specific time points with de-
creased mean PAP included 120, 150, and 180 minutes after
reperfusion (Figure 2). Wet/dry ratios did not differ between
groups (10.3 in controls vs 10.0 PDE inhibition; P ¼ .86).
PDE Inhibition
Control animals had increased PDE5 activity at both 1 and
3 hours after perfusion when compared with measurements
taken before cold storage in the same animals (P< .001 for
each). This translated into decreased levels of both cyclic
GMP (P< .01) and lower PKG activity (P< .01) at 1 and
3 levels after perfusion when compared with prestorage
levels. Animals preconditioned with oral tadalafil, retained
PDE5A activity closer to baseline after 1 and 3 hours of per-
fusion. When PDE5A levels were examined between exper-
imental groups, PDE5A activity at both 1 and 3 hours after
perfusion was significantly greater in tadalafil-treated ani-
mals (Table 2). Consequently, cyclic GMP levels and
PKG activity were significantly higher both before perfusion
and at 1 and 3 hours after perfusion in tadalafil-treated ani-
mals when compared with controls.
ROS
Oral PDE inhibitor preconditioning produced significant
decreases in levels of ROS (as measured by luminol chem-
iluminescence activity assays) at 1 and 3 hours after perfu-
sion. Prestorage and preperfusion luminol activity was not
different between groups (Figure 3).
NOS Signaling
Animals preconditioned with oral tadalafil demonstrated
greater endothelial nitric oxide synthase (eNOS) activityrdiovascular Surgery c Volume 137, Number 5 1251
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.The Journal of Thoracic and Cardiovascularboth before cold storage and at 1 and 3 hours after perfusion.
Conversely, control animals exhibited greater increased in-
ducible nitric oxide synthase (iNOS) activity at 1 and 3 hours
after perfusion (Figure 4).
DISCUSSION
Our experimental model demonstrates that oral donor pre-
treatment with a long-acting PDE inhibitor improves early
pulmonary performance after reperfusion. In our ex vivo de-
sign, rabbits preconditioned with oral tadalafil demonstrated
improved oxygenation and manifested lower PAPs when
compared with controls.
We have demonstrated that oral administration of tadalafil
did in fact inhibit PDE5A activity in the lung. PDE5A
FIGURE 1. Partial pressures of arterial oxygen (A) and carbon dioxide (B)
between control animals (dashed line) and animals treated with tadalafil
(solid black line). Measurements by arterial blood gas sampling were taken
at 15-minute intervals over the course of the experiment. Data points are
mean values with error bars corresponding to standard error of the mean
(SEM). P values were obtained by repeated measures analysis of variance
(RE ANOVA) between groups and modeling with generalized estimating
equation (GEE).Surgery c May 2009
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T
Xactivity increased during reperfusion in control animals yet
remained at baseline in our tadalafil-treated animals. As
would be expected, increases in PDE5 activity in control an-
imals translated to decreases in cyclic GMP and PKG. Addi-
tionally, animals preconditioned with tadalafil had increased
levels of cyclic GMP and PKG.
Finally, we have shown that oxygen-derived free radicals
(as measured by luminol chemiluminescence) are decreased
with PDE inhibition. Oxygen-derived free radicals are im-
portant known mediators of IR injury of the lung.8 They
can lead to direct cellular damage via activation of Ca2þ-
dependent proteases and also contribute to capillary leak
and pulmonary edema.10,20 These findings taken together
FIGURE 2. Mean pulmonary artery pressure (mPAP) between control an-
imals (dashed line) and animals treated with tadalafil (solid black line).
Measurements of mPAP were taken at 15-minute intervals over the course
of the experiment. Data points are mean values with error bars correspond-
ing to standard error of the mean (SEM). P value corresponds to repeated
measures analysis of variance (RM ANOVA) between groups modeling
with generalized estimating equation (GEE).
TABLE 2. Markers of PDE inhibition in lung tissue
Control (n ¼ 9) Tadalafil (n ¼ 6) P value*
PDE5A activity (mP)
Prestorage 123.8  11.3 124.8  11.4 .5
Preperfusion 137.5  5.3 129.3 11.2 .3
1 h after perfusion 163  18.1 134.8  7.2 .001
3 h after perfusion 181.2  31.7 143.3  8.5 .001
cGMP levels (pmol/mg)
Prestorage 1028.3  119.6 1121.5  202.5 .87
Preperfusion 965.6  60.3 1080  167.6 .04
1 h after perfusion 788.4  64.7 1047  187.4 <.001
3 h after perfusion 809.5  123.2 1137.2  475.3 .01
PKG activity (fU/mg)
Prestorage 16.8  2.2 20.2  3.2 .14
Preperfusion 16.4  1.2 19.0  2.7 .03
1 h after perfusion 15.3  2.6 19.0  7.1 <.001
3 h after perfusion 14.2  2.3 25.4  12.2 .005
PDE, Phosphodiesterase; cGMP, cyclic guanosine monophosphate PKG, protein
kinase G; fU, fluorescent units. *P value based on t test comparisons for individual
time points.The Journal of Thoracic and Csuggest a role for donor PDE inhibition in the prevention
and moderation of IR injury after lung transplantation.
The concept of using PDE inhibition against IR injury has
been previously explored. Korom and colleagues21 treated
donor pigs with intravenous sildenafil injected directly into
the PA before experimental lung transplantation. In addition,
sildenafil was placed in the perfusate solution. In their
model, pigs that received sildenafil had improved short-
term survival. Pizanis and colleagues22 investigated the
use of sildenafil administered both intravenously and in
the flush solution before experimental transplantation. In
this model, prerecovery PDE inhibition led to improved
gas exchange in the transplanted organ. However, when sil-
denafil was also given in the preservation solution, it led to
fatal graft failure. In another study by Dutly and associates,23
a selective PDE-4 enzyme inhibitor was introduced into
flush solution before experimental lung transplantation.
Treated animals demonstrated improved airway pressures,
gas exchange, decreased edema, and minimal free radical
injury.
Our study design is unique in that we used an oral precon-
ditioning agent administered to donors hours before lung
harvest. This strategy has advantages for clinical lung trans-
plantation in humans, inasmuch as donor lung harvest is fre-
quently delayed up to several hours owing to a variety of
social, legal, administrative, and clinical factors. Our study
is also unique in that we have made use of tadalafil as our
PDE inhibitor. Because of its long half-life and excellent
oral bioavailability, tadalafil is a drug ideally suited to donor
FIGURE 3. Levels of reactive oxygen species (ROS) as measured by lumi-
nal chemiluminescence activity (relative light units, RLU) at 4 distinct time
points during the experiment. Control animals are seen in the gray shaded
bars, and tadalafil-treated animals are shown with black solid bars. Means
values are provided above the bars with error bars corresponding to standard
deviations. P values correspond to results obtained by comparison of means
via the Student t test.ardiovascular Surgery c Volume 137, Number 5 1253
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T
XFIGURE 4. Nitric oxide synthase (NOS) activity for control (gray shaded bars) versus tadalafil-treated (solid black bars) animals as measured by citruline
formation. Levels of both inducible NOS (iNOS) and endothelial NOS (eNOS) are provided. Means values are provided about the bars with error bars cor-
responding to standard deviations. P values correspond to results obtained by comparison of means via the Student t test.pretreatment. We chose 1 mg (0.25 mg/kg) as our dose be-
cause it fell within the range of doses used in humans for
erectile dysfunction (recommended dose 10–20 mg, 0.15–
0.29 mg/kg assuming 70-kg man, information from Lilly
ICOS, www.cialis.com). Although this dose is slightly
higher than the 0.5- to 0.15-mg/kg range used in studies ex-
amining protection against IR injury with sildenafil,24 we
believed that this higher dose was appropriate given oral ad-
ministration with uncertain bioavailability. We chose to dose
animals 6 hours before harvest and 24 hours before perfu-
sion because tadalafil reaches peak concentrations at 120
minutes in a living organism and lasts up to 36 hours in
the system.
Mechanism of Protection With Selective PDE
Inhibition
Selective PDE5 inhibitors were developed for the
treatment of erectile dysfunction in men. The principal
mechanism of action involves modulation of NO-activated
cyclic GMP by directly inhibiting the PDE enzyme respon-
sible for cyclic GMP breakdown (Figure 5). The resulting in-
creases in cyclic GMP leads to increased activation of PKG,
which phosphorylates downstream targets including recep-
tors, kinases, and phosphatases leading to a variety of cellu-
lar effects.12 PKG has been shown to alter vascular tone and
can serve protective functions within the cell. PKG can in
turn phosphorylate eNOS and iNOS, leading to feedback
regulation of NO production.25,26
Although the biology of PDE activity in the lungs has not
been firmly established, studies examining myocardial1254 The Journal of Thoracic and Cardiovascular Sprotection with PDE5A inhibitors have yielded important in-
sights into potential mechanisms of protection. Specifically,
preconditioning through active PDE inhibition with subse-
quent increases in cyclic GMP and PKG leads to a multitude
of cellular protective effects (Figure 5). PKG can increase
production of adenosine and bradykinin from endothelial
cells, which may lead to donor pulmonary vasodilatation.
This vasodilatation may translate into improved distribution
of preservation solution at the time of recovery. PKG may
also lead to opening of potassium channels (KATP) on the
inner mitochondrial membrane, which can contribute to
cellular stabilization in the face of oxygen-derived free rad-
ical damage.24,27 Increases in cyclic GMP and eNOS may
mediate platelet, neutrophil, macrophage, and leukocyte ad-
hesion. Delayed protection may be a result of PDE5 activa-
tion of the Bcl-2 gene, which has been shown to inhibit
apoptosis.24
NOS Signaling
Our data suggest another important protective mechanism
of PDE5 inhibition involving early preservation of eNOS ac-
tivity and consequent decreases in ROS generation. In this
experiment, both iNOS and eNOS activity were examined
over several time points with treated animals demonstrating
increases in eNOS activity during reperfusion. Conversely,
reperfusion iNOS activity was significantly lower in tadala-
fil-treated animals. These data suggest a protective role of
eNOS and injurious role of iNOS during lung reperfusion.
Others have documented the importance of eNOS and
iNOS in IR injury. Two studies from the University ofurgery c May 2009
Weiss et al Cardiothoracic TransplantationFIGURE 5. Mechanism of NOS signaling and PDE inhibition. Active inhibition of PDE5 by tadalafil leads to increases in cyclic GMP and PKG, which has
a variety of potential protective effects. eNOS, Endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; O2, oxygen; NO, nitric oxide; GC,
guanyl cyclase; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; PDE5, phosphodiesterase type 5; PKG, protein kinase G; ROS,
reactive oxygen species; mitoKATP, mitochondrial potassium channels.T
XToronto lung transplantation group have demonstrated that
eNOS activity levels remain low during reperfusion, sug-
gesting low eNOS levels may be an important mediator of
injury after lung transplantation.28,29 In this group’s experi-
mental model, iNOS was elevated as well, suggesting a po-
tentially injurious role. In additional studies, eNOS has been
described as a critical regulator of NO signaling and impor-
tant for the generation of ROS. This effect, known as NOS
uncoupling, leads to ROS generation in multiple vascular
beds. Donor PDE5 inhibition appears to maintain beneficial
NOS coupling in our experimental model of lung reperfu-
sion. This suggests that activation of PKG and its down-
stream targets may lead to stabilization of beneficial NO
signaling and improved endothelial function.
Role of PDE Biochemistry in Early Reperfusion
Injury
Reperfusion injury has been extensively studied, but our
understanding of PDE biochemistry in lung transplantation
continues to be limited. Pinksy and colleagues30 elegantly
showed the benefits of cyclic GMP levels in early experi-
mental allograft function using PDE5 inhibition. In this
study, the investigators were unable to detect changes in
NOS activity. Our study adds some new observations to
the literature examining this issue. First, PDE5 activity spe-
cifically increases during early reperfusion with consequent
decreases in cyclic GMP levels. This effect does not occur
after cold storage alone. Furthermore, the increase in
PDE5 activity correlates with a dramatic increase in oxida-
tive stress (measured by ROS), decrease in gas exchange,
and increase in PAPs. Increased PDE5 activity further corre-The Journal of Thoracic and Clates with decreased levels of cyclic GMP, and iNOS and
eNOS undergo reciprocal changes in activity during early re-
perfusion, which is reversed by PDE5 inhibition.
From these observations, we can speculate that PDE5
activity is an important factor for early allograft dysfunction
after lung transplantation. Furthermore, the increases in
ROS that we have observed in this model suggest NOS
uncoupling occurs early during reperfusion. Thus, PDE5,
by decreasing levels of cyclic GMP and PKG, likely plays
a crucial role in disturbing the balance between eNOS and
iNOS activity after lung transplantation. These two enzymes
may be pivotal for influencing the magnitude of pulmonary
injury occurring from reperfusion and PDE5 inhibitors may
help to restore normal balance and prevent IR injury.
Study Limitations
Our study is limited by use of a model that is ex vivo in
nature. We do not use immunosuppression, and our animals
have not undergone brain death before harvest. Thus, our
model does not completely replicate in vivo lung transplan-
tation. Inasmuch as we reperfuse for only 3 hours, the effects
we have observed with PDE inhibition may be short-lived,
and we do not know the effects of this therapy for long-
term survival. Further, we do not know whether we have
conducted our experiments using the optimal dose of our
PDE inhibitor. Although we observed a drug effect, we
based our dosing on human dosing and literature, and we
do not know whether a more optimal dose could have
been used or whether dosing should be repeated. We there-
fore will focus future experimentation on dosing levels as
well as redosing. Despite these limitations, we haveardiovascular Surgery c Volume 137, Number 5 1255
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fusion injury of the lungs similar to that seen in clinical lung
transplantation.
CONCLUSIONS
IR injury remains a substantial cause of morbidity and
mortality after lung transplantation. Novel methods to pro-
tect allografts during recovery will not only decrease the
incidence of PGD and chronic graft failure, but also may
embolden centers to use marginal donors with increased
ischemic times, thus increasing the currently limited donor
supply. In this study, we have examined the use of a long-
acting oral PDE inhibitor for donor preconditioning in
a model of IR injury. Our data demonstrate that this strategy
is effective for improving pulmonary performance and de-
creasing oxygen-derived free radical levels after reperfusion.
PDE enzymes and their downstream effectors may play
a critical role in reperfusion injury after lung transplantation.
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Discussion
Dr Christine L. Lau (Charlottesville, Va). My congratulations
to Dr Weiss and the Johns Hopkins group for another outstanding
presentation in the area of lung transplantation.
IR injury remains a major morbidity and potential mortality early
after lung transplantation, and, importantly, now it is known to be
a major risk factor for the development of bronchiolitis obliterans.
In this current study, the authors show in an experimental ex vivo
lung transplant model that oral preconditioning of the donor with
a PDE inhibitor leads to a decrease in IR injury, as evidenced by
markers of PaO2, PAP, and ROS. As pointed out, however, the con-
cept of PDE inhibitors to limit IR injury is not entirely new. Others
have shown similar benefits in the treatment of IR to those de-
scribed in this study with the use of intravenous sildenafil as well
as with other PDE inhibitors, specifically PDE-4 inhibitors. This
current study, however, does add to the previous investigationsrgery c May 2009
Weiss et al Cardiothoracic Transplantationby looking at an oral long-acting agent and thus has some obvious
advantages.
I have two questions. As you know, the primary effect of PDE-5
activity is on cyclic GMP levels and, in turn, stimulation of PKG.
Cyclic GMP also can influence other PDEs that in turn regulate cy-
clic adenosine monophosphate and, thus, lung function. Do you
plan to evaluate the synergy with other cyclic nucleotide PDEs,
for example, PDE-4 inhibition? Second, what are your plans for fu-
ture studies? Do you plan to look at leukocyte trafficking and plate-
let function, histology, and immunohistochemistry, and do you
plan any clinical trials?
Dr Weiss. Thank you, Dr Lau, for your critique and for your
questions and comments.
You bring up an excellent point regarding PDE-4. Certainly
others, including excellent work from the investigators at the
University of Virginia, have looked at activation of the PDE-4
enzyme in models of IR injury. To contrast the difference
between PDE-4 and PDE-5, PDE-4 breaks down cyclic adeno-
sine and PDE-5 breaks down cyclic GMP; PDE-4 is generally
found in inflammatory cells whereas PDE-5 is generally located
in endothelial cells. Although these are generalizations, thinking
about the enzymes in that manner can help us understand their
principal activity. We do not know to what extent tadalafil acts
on PDE-4. I suspect that there is some synergy, and we do
plan to investigate that aspect in future experiments. The answer
to your question is yes. I think that this brings up an opportunity
for dual therapy with both PDE-5 and PDE-4 inhibitors. We
would be interested in exploring that.The Journal of Thoracic and CIn terms of our future directions, we want to make our model
more clinically applicable. For example, we are interested in exam-
ining brain death in our model and we are interested in examining
the effect in a long-term survival model. There is some indication
from our data that the effect may be short-lived, and so we need
to focus on dosing and redosing as well. We are also interested in
looking at platelet function. Finally, we want to examine the role
of PDE enzymes in human lung tissue. We have an approved pro-
tocol at our institution to examine human lung tissue after reperfu-
sion that would have otherwise been discarded. These are some of
the future directions that we are interested in exploring.
Dr Yolonda L. Colson (Boston, Mass). Is most of this effect just
owing to changes in platelet function with your perfusion with the
drug on board, and do you have a control to control for changes in
platelet function?
Dr Weiss. Thank you, Dr Colson, for that question. Although we
know that PDE inhibition can affect platelet function, it is not likely
in our model inasmuch as we are pretreating the donor. We flush
out most of the blood during recovery and it is therefore unlikely
that recipient platelets are exposed to the drug.
Dr. Colson. You could argue that the PDE is just changing plate-
let function, and if you are not having microemboli, your PAP is
lower and your oxygenation is higher.
Dr Weiss. That is true. We did not measure recipient serum
levels of PDE inhibition to prove that the platelets are unaffected.
I think your point is well taken and may be a good reason to give
PDE inhibitors to recipients before transplantation, to decrease
injurious platelet behavior.ardiovascular Surgery c Volume 137, Number 5 1257
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